• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases.

作者信息

Curtis Jeffrey R, Ogdie Alexis, George Michael D

机构信息

University of Alabama at Birmingham.

University of Pennsylvania Medical Center, Philadelphia.

出版信息

JAMA. 2021 May 4;325(17):1726-1728. doi: 10.1001/jama.2021.2740.

DOI:10.1001/jama.2021.2740
PMID:33944889
Abstract
摘要

相似文献

1
Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases.免疫介导性炎症疾病患者的治疗策略
JAMA. 2021 May 4;325(17):1726-1728. doi: 10.1001/jama.2021.2740.
2
Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed.
Aliment Pharmacol Ther. 2019 Mar;49(6):816-817. doi: 10.1111/apt.15081.
3
Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy - early promise but more data needed. Authors' reply.社论：使用治疗药物监测策略降低炎症性肠病患者英夫利昔单抗剂量——初现希望但仍需更多数据。作者回复
Aliment Pharmacol Ther. 2019 Mar;49(6):817-818. doi: 10.1111/apt.15151.
4
Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.治疗药物监测在炎症性肠病中英夫利昔单抗反应丧失的管理中比基于临床的方法更具成本效益：一项观察性多中心研究。
J Crohns Colitis. 2019 Apr 26;13(5):539-540. doi: 10.1093/ecco-jcc/jjy202.
5
Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.治疗药物监测可预测临床缓解的炎症性肠病患者英夫利昔单抗治疗降阶梯后反应丧失的情况。
Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):90-8. doi: 10.1016/j.clinre.2015.05.019. Epub 2015 Jun 29.
6
Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy.接受英夫利昔单抗治疗的炎症性肠病患者中反应性与前瞻性治疗药物监测：自我实现的预言
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1638. doi: 10.1016/j.cgh.2017.05.017. Epub 2017 May 18.
7
Letter: therapeutic drug monitoring and inflammatory bowel disease-a call for an urgent standardization of the results.
Aliment Pharmacol Ther. 2018 Feb;47(3):448-449. doi: 10.1111/apt.14456.
8
Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.采用新西兰检测方法评估英夫利昔单抗和阿达木单抗浓度及抗药物抗体对炎症性肠病的控制效果。
Intern Med J. 2019 Apr;49(4):513-518. doi: 10.1111/imj.14064.
9
Proactive and Reactive Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease Are Complementary, Not Mutually Exclusive.炎症性肠病生物治疗的主动和被动治疗药物监测是互补的，而非相互排斥的。
Clin Gastroenterol Hepatol. 2018 Apr;16(4):597-598. doi: 10.1016/j.cgh.2017.11.033.
10
Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.与反应性监测相比，积极监测英夫利昔单抗血清浓度可改善炎症性肠病患者的长期预后。
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1580-1588.e3. doi: 10.1016/j.cgh.2017.03.031. Epub 2017 Mar 30.

引用本文的文献

1
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.治疗药物监测中的挑战：优化炎症性肠病和其他免疫介导的炎症性疾病患者的生物治疗。
Ther Drug Monit. 2023 Oct 1;45(5):579-590. doi: 10.1097/FTD.0000000000001095. Epub 2023 Apr 3.
2
Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control.类风湿关节炎病情得到良好控制的患者停用传统合成改善病情抗风湿药物
JAMA. 2023 Mar 28;329(12):1024-1026. doi: 10.1001/jama.2023.0492.
3
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine.
评估炎症性关节疾病中生物药物的免疫原性：迈向个体化医学的进展。
BioDrugs. 2022 Nov;36(6):731-748. doi: 10.1007/s40259-022-00559-1. Epub 2022 Oct 31.
4
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.影响英夫利昔单抗产生抗药抗体的因素：一项随机对照试验的二次分析。
J Intern Med. 2022 Sep;292(3):477-491. doi: 10.1111/joim.13495. Epub 2022 Apr 26.
5
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.免疫介导的炎症性疾病患者维持 infliximab 治疗中治疗药物监测与标准治疗对疾病控制的影响：一项随机临床试验。
JAMA. 2021 Dec 21;326(23):2375-2384. doi: 10.1001/jama.2021.21316.